top
   
         
WuXi AppTec's
Global Solutions for Biologics

CLICK HERE TO LEARN MORE
Jerome Zeldis
Chief Medical Officer, Celgene Corp.
CEO, Celgene Global Health
  RuiPing Dong
Senior Vice President,
Head of Emerging Markets R&D, Merck
  Kent Thoelke
Executive Vice President,
Scientific & Medical Affairs, PRA International
  Richard Soll
Senior Vice President of Integrated Services
and Head of Corporate Alliances, WuXi AppTec
 
 
In This Issue
 
 
  Upcoming Global Webcast:
Demystifying Product Development in China

WuXi PharmaTech Corporate Venture Fund Participates in Syros $30M Series A

WuXiPRA Officially Starts Operations

WuXi Receives Merck Awards for Achieving Team Milestones

WuXi Receives Janssen R&D Suppliers Award

WuXi Genome Center Is Poised for Growth

“In China for the World”

Dr. Weichang Zhou Joins WuXi

 

Round Table Discussions with:

Jerome Zeldis, Chief Medical Officer, Celgene Corp. and CEO, Celgene Global Health
RuiPing Dong, Senior Vice President, Head of Emerging Markets R&D, Merck.
Kent Thoelke, Executive Vice President, Scientific & Medical Affairs, PRA International
Moderated by Richard Soll, Senior Vice President of Integrated Services and Head of Corporate Alliances, WuXi AppTec

Event Date: Webinar | June 13, 2013
Time: 8:00am-9:00am PDT, 11:00am-12:00pm EDT, 15:00-16:00 GMT
Registration: Complimentary live webcast open to life science professionals globally

Click Here to Register and Download Full Program

 
     
WuXi Congratulates Professor Yigong Shi
    WuXi PharmaTech Corporate Venture Fund Participates in Syros $30M Series A
Dr. Yigong Shi, an endowed Professor and Dean of the School of Life Sciences at Tsinghua University, has been elected as a foreign academician to the US National Academy of Sciences. Professor Shi was a member of the Selection Committee for the annual “WuXi Life Science and Chemistry Awards”. Congratulations Professor Shi!

Syros Pharmaceuticals, a new startup company based in greater Boston area, raised $30 million funding in April 2013, which was led by ARCH Venture Partners and Flagship Ventures. Syros will use the capital to develop treatments for cancer and other diseases by controlling the switches that regulate gene expression. The WuXi PharmaTech Corporate Venture Fund participated in the funding to help accelerating the discovery and development of these novel gene control medicines.
   
 
  WuXiPRA Officially Starts Operations

We are very pleased to announce that WuXiPRA Clinical Research Co., Ltd., officially began its operations on May 28, 2013. This joint venture brings together PRA's global clinical trial expertise and WuXi's China knowledge to meet the increasing need of sophisticated clinical-trial management services in order to gather the highest-quality data in Chinese patients to complete Chinese and international regulatory filings as quickly and successfully as possible. We aim to become the gateway to our partners' success in China with the highest quality standards and operational excellence.
 
“Every Client is a Partner”
ChinaBio® recently had a chance to talk with Richard Soll on the subject of WuXi's business strategy with a special focus on partnering.
 
   
  WuXi Receives Merck Awards for Achieving Team
Milestones

Four WuXi medicinal chemistry teams received Merck Awards in May 2013 “in recognition of the team's outstanding efforts to achieve a milestone”. It gives us great pleasure to contribute to Merck's drug discovery efforts through our integrated discovery platform. We are honored to receive these recognitions, and look forward to continued delivery of collaboration excellence for our customers and partners.
 

WuXi AppTec's
Clinical & Regulatory Services

CLICK HERE TO LEARN MORE
 
  WuXi Receives Janssen R&D Suppliers Award

We are pleased and honored to receive the Janssen Global Supplier R&D Award in recognition of WuXi's contributions to Janssen's success in a range of research and development projects. Commitment to performance excellence drives everything we do at WuXi, and our unwavering goal is to best serve the world's medical innovators by providing an open platform to enable them to bring new medical treatments to patients around the world more efficiently and effectively.
 
  WuXi Genome Center Is Poised for Growth

Hongye Sun, VP and COO of WuXi's Genome Center discussed with Julia Karow of Genome Web's In Sequence, the rapid progress made in launching genome services. From genomically characterized Chinese patient derived xenograft models, high volume bacterial sample processing, to clinical sample NGS sequencing, the center is integrated upstream and downstream with WuXi's drug discovery and development platforms by working closely with oncology, infectious disease, clinical, and biomarker teams at WuXi.
 
“Transforming Biopharma Innovation via Global Collaboration”
   
Tao Guo, Vice President of Medicinal Chemistry, was invited to speak about WuXi's open-access discovery platform at the special presidential symposium of the 2013 Spring ACS National Meeting - "Vision 2025: How to Succeed in the Global Chemistry Enterprise".

 
“In China For the World”
 
 
In an interview with C&EN, Minzhang Chen, VP and Head of Process R&D and Manufacturing, shared our aspiration to be one of the first CMOs in China able to manufacture new chemical entity APIs for the global market. “we started as a development and research manufacturing service provider back in 2004,” Chen says about WuXi. “As our client base broadened and drug candidates moved to later stages, larger-scale manufacturing—even commercial-scale—was a natural move for WuXi.” Today, the company is manufacturing intermediates for six commercialized drugs and intermediates and APIs for another seven in Phase III clinical trials.
 
 
 
  Dr. Weichang Zhou Joins WuXi
“The China Evolution”
 
 
We are pleased to welcome Dr. Weichang Zhou on board as Vice President of Biologics Process Development. Weichang has over 20 years of broad industrial experience in biologics manufacturing process development, scale-up, characterization, technology transfer, manufacturing and regulatory support. He has provided scientific leaderships to many multifunctional CMC teams in the US by serving as Senior Director of Commercial Cell Culture Development at Genzyme, Senior Director of Process Sciences and Engineering at PDL BioPharma and Associate Director of Fermentation and Cell Culture at Merck.
Richard Soll shared insights with PharmAsia News on China's pharma evolution, and the transition of WuXi from chemistry services to fully integrated technology and capability platform
   

Thank you for reading this issue of WXPress, and for your support in helping WuXi reach where we are today. We will continue with our goal - to serve you better with our integrated technology and capability platform.

Office of Corporate Alliances and Office of Corporate Communications, WuXi AppTec

Web: www.wuxiapptec.com
Email:mailto:wxpress@wuxiapptec.com